subject: An Overview Of European Drug Packaging Materials Market [print this page] It is estimated that the whole of Europe (including Eastern Europe) with annual sales of pharmaceutical packaging materials market reached 3.246 billion U.S. dollars. The main form of packaging containers and cardboard boxes, each of total sales each 1 / 4; followed by blister packaging (including PVC articles and pouches), accounting for 22%; the rest of the seal from the bottle, label, and other categories drug delivery systems in the country. For materials, paper and board sales accounted for 37% of sales accounted for 28% of plastic, metal sales accounted for 26% and glass sales accounted for only 9%.
From the present to 2007, sales of packaging materials and drug sales are expected to increase in parallel to reduce the packaging weight of the negative effects of high-value package will be balanced by the tide. In fact, packaging, sales, pharmaceutical sales grew much faster than, albeit not too much. This is because pharmaceutical companies are willing to buy more expensive, more secure, anti-sabotage, anti-child abuse, to facilitate and to protect the privacy of the elderly taking packaging.
Thus, in 1998, 3.2 billion U.S. dollars compared with 2002 sales of pharmaceutical packaging up to 40 billion U.S. dollars in 2007 to reach 5.1 billion. Here in the first half period, 5% to 6% growth rate will be the next 10 years into the latter half of 4%. Glass products accounted for 9% of annual sales. Cayey pharmaceutical glass vial being plastic challenge, but the glass excellent barrier properties and better compensate for their sense of distinctiveness may often be fragile defects.
Packaging trend of development of the glass industry, have complex effects, because the glass was seen as better quality than the plastic packaging materials. For drug makers, the image is becoming a priority aspect. On the contrary, this trend is to enable the container to the blister packaging changes. Was slow, but it is likely to increase the pace. In the UK, pharmacists have traditionally re-packing the tablets into the bottle of operations will be banned. As mentioned above, is used to re-packing tablets are often plastic bottles now.
As the sales of glass packaging regulations impact of short-term there will be a reduction in usage by 2007 will further decrease slightly. However, the stability of the product would continue to use glass packaging, not only because of its good quality, but also because a number of pharmaceutical packaging is concerned, in reality there is no room for choice.
There will be a trend against the use of medicinal glass bottles, even if it seems can not be challenged in the glass cases (such as cough syrup package), some pharmaceutical companies are beginning to accept the validity of a shorter product, has access to the benefits of plastic packaging. Can be used to produce safety glass bottles, vials and syringes. In fact, only 5% of these products are made from non-glass materials. This has become a major market for glass industry, and in terms of quantity and value accounted for the bulk. As many can only be administered by a non-oral means of recombinant DNA product development, security and the production of bottles and vials begun to grow. However, with the powder and liquid needle-free injection system development, common use of syringes will fall.
In the glass type and use there would be no progress, but there are competing ways of transmission of drugs can reduce the number and type of injection of the progress, especially in Europe, including nasal sprays, inhalants, oral form (usually the enteric coated), transdermal patches and non-needle injection delivery system, it will affect the sales of glass packaging.
An Overview Of European Drug Packaging Materials Market
